Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper

G. Girolomoni, C. E.M. Griffiths, J. Krueger, F. O. Nestle, J. F. Nicolas, J. C. Prinz, L. Puig, M. Ståhle, P. C.M. Van De Kerkhof, M. Allez, P. Emery, C. Paul

Research output: Contribution to journalReview articleResearchpeer-review

37 Citations (Scopus)


© 2015 The Author(s). Psoriasis is an immune-mediated inflammatory disease (IMID) which may have a major impact on a patient's life, especially when the disease is moderate to severe. There is evidence that treatment of psoriasis during the first years is conservative and frequently based on topical agents which rarely clear lesions. Treatment with systemic agents including biologics is often undertaken only when topical agents have proved unsuitable, even in patients with moderate to severe disease. However, there is evidence that in other IMIDs (rheumatoid arthritis and Crohn's disease), targeted systemic treatment given early in the treatment pathway may improve long-term patient outcomes. We hypothesize that a patient-centered therapeutic approach, undertaken early in the psoriasis treatment pathway ("early intervention") with the goal of complete clearance, may improve control of cutaneous symptoms and may also modify disease course and burden. Critical points to address when designing an early intervention study would include: the definition of psoriasis disease activity; patient selection; intervention selection; and dosing strategies.
Original languageEnglish
Pages (from-to)103-112
JournalJournal of Dermatological Treatment
Issue number2
Publication statusPublished - 1 Apr 2015


  • Comorbidities
  • Early intervention
  • Management
  • Pathophysiology
  • Psoriasis


Dive into the research topics of 'Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper'. Together they form a unique fingerprint.

Cite this